$8.05
+0.01 (+0.06%)
Open$8.15
Previous Close$8.05
Day High$8.15
Day Low$8.00
52W High$42.79
52W Low$5.67
Volume—
Avg Volume30.2K
Market Cap54.56M
P/E Ratio—
EPS$-10.78
SectorBiotechnology
Analyst Ratings
Buy
7 analysts
Price Target
-0.2% upside
Current
$8.05
$8.05
Target
$8.03
$8.03
$5.28
$8.03 avg
$9.44
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 12.19M | 11.47M | 10.10M |
| Net Income | 876.0K | 905.7K | 740.1K |
| Profit Margin | 7.2% | 7.9% | 7.3% |
| EBITDA | 1.90M | 1.88M | 1.67M |
| Free Cash Flow | 486.5K | 519.3K | 559.1K |
| Rev Growth | +7.7% | +14.6% | +19.0% |
| Debt/Equity | 1.27 | 1.35 | 1.37 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |